CPP (Cancer Prevention Pharmaceuticals) Net Income (Continuing Operations) : $-5.72 Mil (TTM As of Mar. 2016)

View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Cancer Prevention Pharmaceuticals's Net Income (Continuing Operations) for the three months ended in Mar. 2016 was $-3.32 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2016 was $-5.72 Mil.

Cancer Prevention Pharmaceuticals Net Income (Continuing Operations) Historical Data

The historical data trend for Cancer Prevention Pharmaceuticals's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Prevention Pharmaceuticals Net Income (Continuing Operations) Chart

Cancer Prevention Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Net Income (Continuing Operations)

-2.95

-6.00

-5.68

Cancer Prevention Pharmaceuticals Quarterly Data
	Dec13	Dec14	Mar15	Sep15	Dec15	Mar16
Net Income (Continuing Operations)	Get a 7-Day Free Trial			-1.61	-2.01	-	-2.40	-3.32

Cancer Prevention Pharmaceuticals Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.72 Mil.

Cancer Prevention Pharmaceuticals (AMEX:CPP) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Cancer Prevention Pharmaceuticals Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Cancer Prevention Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.canprevent.com

Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.